Larvol Delta - Bispecic-vs-Bispecic-Innovent-Announces-First-Patient-Dosed-in-the-Phase-2-Clinical-Study-of-Efdamrofusp-Alfa-IBI302-a-Firstinclass-AntiVEGF-and-AntiComplement-Bispecic-Fusion-Protein-for-the-Treatment-of-Diabetic-Macular-Edema

efdamrofusp alfa (IBI-302) - Innovent Biologics

https://www.prnewswire.com/news-releases/bispecific-vs-bispecific-innovent-announces-first-patient-dosed-in-the-phase-2-clinical-study-of-efdamrofusp-alfa-ibi302-a-first-in-class-anti-vegf-and-anti-complement-bispecific-fusion-protein-for-the-treatment-of-diabetic-m-302445995.html

May 6, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next